Personalized gene therapies for children are being prepared for trials in early 2027
Personalized gene therapies for children are being prepared for trials in early 2027
The program will initially treat eight children with severe inherited immune and metabolic disorders. In an interview on November 17, Fyodor Urnov, a geneticist at the University of California, Berkeley, described preliminary discussions with the FDA about the program. Patients are expected to receive treatment at the University of California, San Francisco.
While researchers were preparing a therapy for one child, his condition deteriorated. His doctors decided to proceed with standard treatment because waiting for the experimental therapy had become too dangerous. Urnov recalled their words: “We cannot wait for your gene therapy.”
In July 2025, the Chan Zuckerberg Initiative announced a grant of 20 million dollars for a center developing personalized gene therapies for children. The center brings together gene editor development in Berkeley, clinical care in San Francisco, and component manufacturing. The team aims to establish manufacturing and testing procedures that can be reused in part for subsequent patients.
A CRISPR editor changes DNA at a specified site. A guide RNA directs it to that site by recognizing the target DNA sequence. If the next child has a different mutation in the same gene and the same editor is suitable, changing twenty “letters” in the guide is enough to redirect it. The editor protein and manufacturing process can remain the same: the part that specifies where the edit occurs is personalized.
The program has a clinical precedent: in 2025, a personalized CRISPR therapy for an infant was developed in about six months. Its developers proposed retaining the components shared by these therapies while changing the guide to match the next patient's mutation.
This RNA still has to be manufactured to pharmaceutical quality standards. Industry can produce large batches of identical RNA, but this program needs a small batch of RNA tailored to each patient's mutation. The team is working with manufacturing company Danaher to develop methods for this small-scale production.
Another task is to assemble the evidence needed for permission to begin trials. Urnov estimates that preparing to treat the first child took three years of work and millions of dollars. For the next child, he proposes reusing the established manufacturing process and testing methods: “Can we focus on reducing the risks associated with what we changed?” Changing the guide also changes the set of DNA sites the editor could affect unintentionally. The FDA draft guidance proposes using existing testing methods to assess the risks of each new guide and editor pairing separately.
The center has pledged to share research data and regulatory documents for trial authorization with other university children's hospitals in the US. These hospitals could then draw on that work when developing their own therapies for similar patients.